U.S. court finds Novo Nordisk Prandin diabetes drug patent invalid

(Reuters) – A U.S. appeals court found the patent on Novo Nordisk’s Prandin diabetes drug in combination with metformin to be invalid, paving the way for introduction of a generic version of the medicine, the Danish drugmaker said on Tuesday. In a 2-1 ruling, the U.S. Court of Appeals affirmed a district court ruling handed down in 2011, the company said. Novo said it still believes the patent to be valid and was reviewing the ruling. …